nach oben

International Ophthalmology

Erschienen in:

27.03.2023 | Review

Effect of topical motesanib in experimental corneal neovascularization model

verfasst von: Mukaddes Çelenk, Hakan Yıldırım, Ahmet Tektemur, Mehmet Balbaba, Murat Erdağ

Erschienen in: International Ophthalmology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to compare the efficacy of topical bevacizumab and motesanib in an experimental corneal neovascularization model, and find the most effective motesanib dose.

Materials and methods

In experiments, 42 Wistar Albino rats were randomly divided into six groups (n = 7). Corneal cauterization was applied to all groups except the group 1. Group 1 did not receive any treatment. Topical dimethylsulfoxide was applied to sham group three times a day(tid). Topical bevacizumab drops (5 mg/ml) were applied to Group 3 tid. Topical motesanib drops with a dose of 2.5, 5, and 7.5 mg/ml were respectively applied in Groups 4, 5, and 6 tid. On the 8th day, corneal photographs of all rats were taken under general anesthesia, and the percentage of corneal neovascular area was calculated. VEGF-A mRNA, VEGFR-2 mRNA, miRNA-21, miRNA-27a, miRNA-31, miRNA-126, miRNA-184, and miRNA-204 were evaluated by the qRT-PCR method in corneas taken after decapitation.

Results

The percentage of corneal neovascularization areas and VEGF-A mRNA expression levels were decreased in all treatment groups compared to group 2 (p < 0.05). VEGFR-2 mRNA levels were found to be statistically significantly decreased in groups 4 and 6 compared to group 2 (p < 0.05). Statistically significant changes were detected in the expression levels of only miRNA-126 among all miRNAs.

Conclusion

Motesanib with a dose of 7.5 mg/ml statistically significantly suppressed the VEGFR-2 mRNA level compared with other treatment doses and may be more effective than bevacizumab. Further, miRNA-126 can be used as a proangiogenic marker.

Zhang SX, Ma JX (2007) Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 26:1–37CrossRefPubMed

Feizi S, Azari AA, Safapour S (2017) Therapeutic approaches for corneal neovascularization. Eye and Vision 4:1–10CrossRef

Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Investig Ophthalmol Visual Sci 41:2514–2522

Ho QT, Kuo CJ (2007) Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 39:1349–1357CrossRefPubMedPubMedCentral

Gan L, Fagerholm P, Palmblad J (2004) Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 82:557–563CrossRefPubMed

Scholl S, Kirchhof J, Augustin AJ (2010) Antivascular endothelial growth factors in anterior segment diseases. Anti-VEGF. Karger Publishers, vol 46, pp 133–139

Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854CrossRefPubMed

Zhang Y, Cai S, Jia Y, Qi C, Sun J, Zhang H et al (2017) Decoding noncoding RNAs: role of microRNAs and long noncoding RNAs in ocular neovascularization. Theranostics 7:3155–3167CrossRefPubMedPubMedCentral

Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB et al (2009) Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res 28(2):117–144CrossRefPubMed

10.

Montanino A, Manzo A, Carillio G, Palumbo G, Esposito G et al (2021) Angiogenesis inhibitors in small cell lung cancer. Front Oncol 11:655316CrossRefPubMedPubMedCentral

11.

Li C, Kuchimanchi M, Hickman D, Poppe L, Hayashi M, Zhou Y et al (2009) In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans. Drug Metab Dispos 37:1378–1394CrossRefPubMed

12.

Sawaki A, Yamada Y, Komatsu Y, Kanda T, Koseki M, Baba H et al (2010) Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Cancer Chemother Pharmacol 65:961–967CrossRefPubMed

13.

Sherman SI, Wirth LJ, Droz J-P, Hofmann M, Bastholt L, Martins RG et al (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31–42CrossRefPubMed

14.

Tektemur A, Etem Önalan E, Kaya Tektemur N, Dayan Cinkara S, Kılınçlı Çetin A, Tekedereli et al (2021) Carbamazepine-induced sperm disorders can be associated with the altered expressions of testicular KCNJ11/miR-let-7a and spermatozoal CFTR/miR-27a. Andrologia 53:e13954CrossRefPubMed

15.

Prasadam I, Zhou Y, Du Z, Chen J, Crawford R, Xiao Y (2014) Osteocyte-induced angiogenesis via VEGF–MAPK-dependent pathways in endothelial cells. Mol Cell Biochem 386:15–25CrossRefPubMed

16.

Kamanu TK, Radovanovic A, Archer JA, Bajic VB (2013) Exploration of miRNA families for hypotheses generation. Sci Rep 3:1–8CrossRef

17.

Mukwaya A, Jensen L, Peebo B, Lagali N (2019) MicroRNAs in the cornea: role and implications for treatment of corneal neovascularization. Ocular Surface 17:400–411CrossRefPubMed

18.

Wang L, Lee AYW, Wigg JP, Peshavariya H, Liu P, Zhang H (2016) miR-126 regulation of angiogenesis in age-related macular degeneration in CNV mouse model. Int J Mol Sci 17:895CrossRefPubMedPubMedCentral

19.

Bai Y, Bai X, Wang Z, Zhang X, Ruan C, Miao J, (2011) MicroRNA-126 inhibits ischemia-induced retinal neovascularization via regulating angiogenic growth factors. Exp Mol Pathol 91:471–477CrossRefPubMed

20.

Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ et al (2008) Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 135:3989–39893CrossRefPubMed

21.

Yaşar M, Çakmak H, Dündar S, Örenay Boyacıoğlu S, Çalışkan M, Ergin K (2020) The role of microRNAs in corneal neovascularization and its relation to VEGF. Cutan Ocul Toxicol 39(4):341–347CrossRefPubMed

22.

Liu C-H, Huang S, Britton WR, Chen J (2020) MicroRNAs in vascular eye Diseases. Int J Mol Sci 21:649CrossRefPubMedPubMedCentral

23.

Zhang Y, Zhang T, Ma X, Zou J (2017) Subconjunctival injection of antagomir-21 alleviates corneal neovascularization in a mouse model of alkali-burned cornea. Oncotarget 8:11797–11808CrossRefPubMed

24.

Urbich C, Kaluza D, Frömel T, Knau A, Bennewitz K, Boon RA et al (2012) MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood J Am Soc Hematol 119:1607–1616

25.

Chen P, Yin H, Wang Y, Wang Y, Xie L (2012) Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1α in a mouse model of closed eye contact lens wear. Mol Vis 18:864–873PubMedPubMedCentral

26.

Zhang X, Di G, Dong M, Qu M, Zhao X, Duan H et al (2018) Epithelium-derived miR-204 inhibits corneal neovascularization. Exp Eye Res 167:122–127CrossRefPubMed

27.

Zong R, Zhou T, Lin Z, Bao X, Xiu Y, Chen Y et al (2016) Down-regulation of MicroRNA-184 is associated with corneal neovascularization. Invest Ophthalmol Vis Sci 57(3):1398–1407CrossRefPubMed

28.

Al-Debasi T, Al-Bekairy A, Al-Katheri A, Al Harbi S, Mansour M (2017) Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. Saudi J Ophthalmol 31:99–105CrossRefPubMedPubMedCentral

29.

Habot-Wilner Z, Barequet IS, MoisseievJ, Rossner M IY (2010) The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 88:862–867CrossRefPubMed

30.

Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28–39CrossRefPubMed

31.

Pawson T (2002) Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38:3–10CrossRef

32.

Yildirim H, Aydemir O, Balbaba M, Özercan IH, Ilhan N (2020) Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization. Cutan Ocul Toxicol 39:223–228CrossRefPubMed

33.

Sahan B, Ciftci F, Eyuboglu S, Yilmaz B, Yalvac BI (2019) Comparison of the effects of dovitinib and bevacizumab on reducing neovascularization in an experimental rat corneal neovascularization model. Cornea 38:1161–1168CrossRefPubMed

34.

Cakmak H, Gokmen E, Bozkurt G, Kocaturk T, Ergin K (2018) Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization. Cutan Ocul Toxicol 37(2):191–195CrossRefPubMed

35.

Rho CR, Kang S, Park KC, Yang KJ, Choi H, Cho WK (2015) Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice. J Ocul Pharmacol Ther 31:25–31CrossRefPubMedPubMedCentral

36.

Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L et al (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Can Res 66:8715–8721CrossRef

37.

Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J (2012) Anti-tumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest 35:181–190PubMed

38.

Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K et al (2009) Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res 15:110–118CrossRefPubMed

39.

Tebbutt N, Kotasek D, Burris HA, Schwartzberg LS, Hurwitz H, Golstein SJ, D, (2015) Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 75:993–1004CrossRefPubMed

40.

Dell S, Peters S, Müther P, Kociok N, Joussen AM (2006) The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci 47:1928–1937CrossRefPubMed

Titel: Effect of topical motesanib in experimental corneal neovascularization model
verfasst von: Mukaddes Çelenk
Hakan Yıldırım
Ahmet Tektemur
Mehmet Balbaba
Murat Erdağ
Publikationsdatum: 27.03.2023
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 8/2023
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-023-02685-3

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effect of topical motesanib in experimental corneal neovascularization model

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

CME: Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Objective cataract grading methods and expected contrast sensitivity reestablishment with multifocal intraocular lenses

Morphological changes of foveal cysts as a predictor for visual response to anti-vascular endothelial growth factor treatments in diabetic macular edema

Quality analysis of YouTube videos about thyroid orbitopathy

Intraoperative primary partial occlusion of the PreserFlo MicroShunt to prevent initial postoperative hypotony

Functional epiphora: an under-reported entity

Panuveitis of undetermined origin after diagnostic pars plana vitrectomy: clinical characterization and long-term outcome from a tertiary referral center

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

CME: Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde